Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Behavioral Neurology & Neuropsychiatry
How does the microbiome factor into neurodegenerative diseases?
Related Questions
What is the minimum level of cognitive symptoms that would prompt you to pursue biomarker testing required for anti-amyloid therapies for Alzheimer's?
What would prompt discontinuing treatment versus switching or sequencing treatment in patients treated with an anti-amyloid therapy for Alzheimer's?
Is a history of coronary artery disease and afib a contraindication to using donepezil?
How do you limit impact of the language barrier in patients being assessed for cognitive changes?
What is your approach to patients who develop ARIA-E or ARIA-H during treatment with anti-amyloid therapies?
How do you approach an isolated increased protein levels in the CSF in patients with cognitive decline?
How do you approach patients with recurrent TGA in the emergency room?
Do you get volumetric MRI in all patients with cognitive difficulties?
What are the best practices for centers interested in providing anti-amyloid therapies for early Alzheimer's to ensure treatment delivery success?
Do you recommend thiamine for patients presenting with acute symptoms of TGA?
